BTIG analyst Thomas Shrader lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $35 and keeps a Buy rating on the shares after the company announced topline data from the Phase 2 ...
JPMorgan says that following Hindenburg Research’s short report on Carvana (CVNA), the key debates are now centered around four topics: Ally Financial (ALLY) partnership viability and new loan partner ...
Exxon Mobil (NYSE: XOM) stock fell 0.7% after the oil major warned that a decline in oil refining profits, along with weak ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback